YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Upstream Bio (UPB [https://seekingalpha.com/symbol/UPB]) shares jumped 8% in premarket trading on Tuesday, after the company said it showcased Phase 2 VALIANT trial data for its severe asthma candidate, verekitug, during a late-breaking…
Upstream Bio – Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company's P…
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Upstream Bio, Inc. (NASDAQ:UPB) is one of the most promising stocks on our list. TheFly reported on June 3 that H.C. Wainwright analyst…
Upstream Bio, Inc. (NASDAQ:UPB) is among the best low priced stocks to get rich in 2026. On June 12, JPMorgan significantly trimmed the price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35, while downgrading the stock from Overwe…
(RTTNews) - Upstream Bio Inc. (UPB) reported new responder analyses from its Phase 2 VIBRANT trial showing that a significant majority of patients with chronic rhinosinusitis with nasal polyps experienced clinically meaningful improvements…
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful i…
* Upstream Bio, Inc. press release [https://seekingalpha.com/pr/20512912-upstream-bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights] (UPB [https://seekingalpha.com/symbol/UPB]): Q1 Revenue of $1.03M. * Net los…
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurrin…
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcom…
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. Super Micro Computer What happened? On Monday, Northland downgraded Super Micro Computer Inc (NASDAQ:SMCI) to Market Perform with a $…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Citi upgraded Bilibili (BILI) to Buy from…
On February 17, 2026, ENAVATE Sciences GP, LLC disclosed a buy of 157,800 shares of Zenas BioPharma(NASDAQ:ZBIO), an estimated $5.19 million trade based on quarterly average pricing. ENAVATE Sciences added 157,800 shares of Zenas BioPharma…
The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates. Advancements in biologic therapies are expanding treatment options and significantly…
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses,…
[Wall street sign on manhattan] franckreporter/iStock via Getty Images With the Q4 earnings season almost coming to an end, below is a list of small-cap stocks with positive quarterly EPS surprises ranked according to their lowest Seeking…
Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen. Continue Reading
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will re…
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand…
* Upstream Bio, Inc. press release [https://seekingalpha.com/pr/20293969-upstream-bio-reports-third-quarter-2025-financial-results-and-highlights-continued-progress] (UPB [https://seekingalpha.com/symbol/UPB]): Q3 Revenue of $0.68M beats b…
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 w…
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data suppo…
We came across a bullish thesis on Upstream Bio, Inc. on Value investing subreddit by Dizzy_Drawing_2451. In this article, we will summarize the bulls’ thesis on UPB. Upstream Bio, Inc.'s share was trading at $19.97 as of September 5th.Cou…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand…
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT ST…
(RTTNews) - Upstream Bio, Inc. (UPB) Tuesday announced positive top-line results from Phase 2 VIBRANT study evaluating verekitug in people with chronic rhinosinusitis with nasal polyps. The study met its primary goal showing statistically…
– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS)…
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will r…
Upstream Bio Inc. (NASDAQ:UPB) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 8, Upstream Bio announced that the first patient had been dosed in a Phase 2 clinical trial of verekitug for the treatme…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
Key Points Verekitug Phase 2 trial enrollment milestones completed in severe asthma and CRSwNP; key efficacy data anticipated in Q3 2025 and Q1 2026. Research and development expenses surged 168.8% (GAAP) year over year as clinical progres…
* Upstream Bio, Inc. press release [https://seekingalpha.com/pr/20190646-upstream-bio-reports-second-quarter-2025-financial-results-and-highlights-continued-progress] (NASDAQ:UPB [https://seekingalpha.com/symbol/UPB]): Q2 Revenue of $0.9M.…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Thor Industries, Inc. (Symbol: THO), where a total of 6,999 contracts have traded so far, representing approximately 699,900 under…
WALTHAM, Mass. - Upstream Bio, Inc. (NASDAQ:UPB) has dosed the first patient in its Phase 2 clinical trial evaluating verekitug for chronic obstructive pulmonary disease (COPD), the company announced Tuesday. The clinical-stage biotech com…
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthen…
“ Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab “ “ Supports potentially differentiat…